株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Ascendis Pharma A/Sの製品パイプライン分析

Ascendis Pharma A/S - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256086
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Ascendis Pharma A/Sの製品パイプライン分析 Ascendis Pharma A/S - Product Pipeline Review - 2015
出版日: 2015年04月29日 ページ情報: 英文 33 Pages
概要

Ascendis Pharma A/Sはデンマークに本社をおくバイオテクノロジー企業で、Transconプロドラッグ技術プラットフォームを利用することで、プロドラッグから分化した高付加価値製剤の開発を行っています。主な治療分野は内分泌系、中枢神経系、感染症です。

当レポートでは、Ascendis Pharma A/Sにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Ascendis Pharma A/Sの基本情報

  • Ascendis Pharma A/Sの概要
  • 主要情報
  • 企業情報

Ascendis Pharma A/S:R&Dの概要

  • 主な治療範囲

Ascendis Pharma A/S:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Ascendis Pharma A/S:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Ascendis Pharma A/S:薬剤プロファイル

  • ACP-001
  • ACP-005
  • ACP-006
  • ACP-007
  • ACP-008

Ascendis Pharma A/S:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Ascendis Pharma A/S:最新のパイプライン情報

Ascendis Pharma A/S:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07023CDB

Summary

Global Markets Direct's, 'Ascendis Pharma A/S - Product Pipeline Review - 2015', provides an overview of the Ascendis Pharma A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ascendis Pharma A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ascendis Pharma A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ascendis Pharma A/S's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ascendis Pharma A/S's pipeline products

Reasons to buy

  • Evaluate Ascendis Pharma A/S's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ascendis Pharma A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ascendis Pharma A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ascendis Pharma A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ascendis Pharma A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ascendis Pharma A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ascendis Pharma A/S Snapshot
    • Ascendis Pharma A/S Overview
    • Key Information
    • Key Facts
  • Ascendis Pharma A/S - Research and Development Overview
    • Key Therapeutic Areas
  • Ascendis Pharma A/S - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Ascendis Pharma A/S - Pipeline Products Glance
    • Ascendis Pharma A/S - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ascendis Pharma A/S - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Ascendis Pharma A/S - Drug Profiles
    • ACP-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • treprostinil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pramipexole dihydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ACP-008
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ascendis Pharma A/S - Pipeline Analysis
    • Ascendis Pharma A/S - Pipeline Products by Target
    • Ascendis Pharma A/S - Pipeline Products by Route of Administration
    • Ascendis Pharma A/S - Pipeline Products by Molecule Type
    • Ascendis Pharma A/S - Pipeline Products by Mechanism of Action
  • Ascendis Pharma A/S - Recent Pipeline Updates
  • Ascendis Pharma A/S - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ascendis Pharma A/S, Key Information
  • Ascendis Pharma A/S, Key Facts
  • Ascendis Pharma A/S - Pipeline by Indication, 2015
  • Ascendis Pharma A/S - Pipeline by Stage of Development, 2015
  • Ascendis Pharma A/S - Monotherapy Products in Pipeline, 2015
  • Ascendis Pharma A/S - Partnered Products in Pipeline, 2015
  • Ascendis Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2015
  • Ascendis Pharma A/S - Out-Licensed Products in Pipeline, 2015
  • Ascendis Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Ascendis Pharma A/S - Phase II, 2015
  • Ascendis Pharma A/S - Phase I, 2015
  • Ascendis Pharma A/S - Preclinical, 2015
  • Ascendis Pharma A/S - Discovery, 2015
  • Ascendis Pharma A/S - Pipeline by Target, 2015
  • Ascendis Pharma A/S - Pipeline by Route of Administration, 2015
  • Ascendis Pharma A/S - Pipeline by Molecule Type, 2015
  • Ascendis Pharma A/S - Pipeline Products by Mechanism of Action, 2015
  • Ascendis Pharma A/S - Recent Pipeline Updates, 2015
  • Ascendis Pharma A/S, Subsidiaries

List of Figures

  • Ascendis Pharma A/S - Pipeline by Top 10 Indication, 2015
  • Ascendis Pharma A/S - Pipeline by Stage of Development, 2015
  • Ascendis Pharma A/S - Monotherapy Products in Pipeline, 2015
  • Ascendis Pharma A/S - Out-Licensed Products in Pipeline, 2015
  • Ascendis Pharma A/S - Pipeline by Top 10 Target, 2015
  • Ascendis Pharma A/S - Pipeline by Top 10 Route of Administration, 2015
  • Ascendis Pharma A/S - Pipeline by Top 10 Molecule Type, 2015
  • Ascendis Pharma A/S - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top